The exposure of somapacitan, a long-acting growth hormone, was compared between adults with kidney or hepatic function impairment and their healthy counterparts.

Somapacitan exposure was considerably higher in subjects with severe kidney impairment and those who required hemodialysis than those with normal kidney function, and significantly higher in subjects with moderate hepatic impairment versus those with normal hepatic function.

As the somapacitan dose is to be individually titrated, this higher observed exposure will be taken into account in patients with impaired kidney or hepatic function.